On May 19, who announced that Cansino Biologics Inc(688185) covid-19 vaccine (adenovirus vector covid-19 vaccine kweisa) would be included in the "emergency use list" Cansino Biologics Inc(688185) thus became the third Chinese covid-19 vaccine authorized by who for emergency use after Sinopharm and Kexing inactivated vaccine, and also the 11th covid-19 vaccine authorized in the world.
Cansino Biologics Inc(688185) vaccine is a single dose covid-19 vaccine, which can be used for people over 18 years old Cansino Biologics Inc(688185) vaccine will complete the pre-trial meeting procedures before the submission and submission of the letter of intent in the first half of 2021, start the rolling data evaluation, and become a candidate vaccine for the WHO emergency use list. By the time it was finally approved to be included in the "emergency use list", it had gone through a complex approval process.
Cansino Biologics Inc(688185) vaccine was approved by the State Food and Drug Administration of China in February 2021 with conditions attached. At present, it has obtained the emergency use approval from Mexico, Pakistan, Chile and other countries, and obtained the EU GMP certification.
Wang Yu, former director of China CDC, previously said that only after obtaining the emergency use certification of who can the vaccine be eligible for global procurement or global distribution through covid-19 pneumonia vaccine implementation plan (covax). If the relevant vaccine is not certified by who, there is also a risk that the vaccinator will have limited movement when traveling internationally.
Who introduced on its official website that the technical advisory group of who emergency use list evaluated the quality, safety and effectiveness of Cansino Biologics Inc(688185) vaccine and determined that Cansino Biologics Inc(688185) vaccine meets the WHO standard for the prevention of covid-19 pneumonia, and the benefits of the vaccine far outweigh the risks. Who also introduced that the protection rate of Cansino Biologics Inc(688185) covid-19 vaccine was 64%, and the protection rate for severe cases was 92%. So far, who has approved the emergency use of 11 covid-19 vaccines worldwide, of which 3 are from China, including Sinopharm, Kexing and Cansino Biologics Inc(688185) . Keweisha included in the list is the only covid-19 vaccine of the third generation technology route approved in China.
